Commercially supplied as (S)-1-tert-butyl 2-methyl 5-oxopyrrolidine-1,2-dicarboxylate, CAS 108963-96-8, molecular weight 243.26, the material is hydrolysed in tetrahydrofuran/water at 0–25 °C with pH maintained between 10.0 and 11.0, giving (S)-1-(tert-butoxycarbonyl)-5-oxopyrrolidine-2-carboxylic acid without lactam ring opening. Lithium hydroxide monohydrate is charged at 1.05–1.15 mol equivalents relative to ester; reverse-phase HPLC is used until residual starting material is ≤0.5 area percent. Acidification with 6 M hydrochloric acid to pH 2.5–3.0 releases the free acid, which is extracted into methyl tert-butyl ether or ethyl acetate and concentrated at a jacket temperature not exceeding 35 °C. The resulting N-Boc-L-pyroglutamic acid is coupled to L-histidyl-L-prolinamide using EDC hydrochloride and 1-hydroxybenzotriazole in dimethylformamide at 0–5 °C; coupling reagent charge is 1.2 mol equivalents relative to acid and N,N-diisopropylethylamine is held at 2.0–2.5 mol equivalents. After coupling, the Boc group is removed under acidic conditions, yielding the pyroglutamyl-histidyl-prolinamide motif of protirelin and related thyrotropin-releasing hormone analogues. Pharmaceutical intermediate handling requires an ICH Q3D elemental impurity risk assessment, residual solvent monitoring under USP <467> for tetrahydrofuran and methyl tert-butyl ether, and related substance reporting under ICH Q3A. Jacketed glass-lined reactors with pH-controlled dosing and chilled extraction trains are the typical production equipment; the hydrolytic stage is the main point of batch-to-batch yield variance if the pH exceeds 11.5 or the temperature rises above 25 °C before acidification.

What Limits the Yield of C-2 Quaternary Substitution in N-Boc-Pyroglutamate Ester Chemistry?

Deprotonation at C-2 of (S)-1-tert-butyl 2-methyl 5-oxopyrrolidine-1,2-dicarboxylate is performed with lithium diisopropylamide or lithium hexamethyldisilazide in anhydrous tetrahydrofuran at −78 °C to −65 °C. The base charge is held at 1.05–1.20 mol equivalents relative to substrate, and the alkylating agent — typically benzyl bromide, allyl bromide, or methyl iodide — is introduced at 1.1–1.5 mol equivalents after a 45–60 min enolisation period. Residual water in the solvent must be ≤0.1 % w/w because protonation of the lithium enolate returns starting material with loss of the original C-2 stereocentre. The ester group remains intact during the alkylation sequence; subsequent hydrolysis and Boc removal deliver 2-substituted pyroglutamic acid derivatives used as constrained γ-lactam amino acid building blocks in peptidomimetic lead optimisation. Chiral integrity of the quaternary centre is confirmed by chiral HPLC under USP <621> conditions; diastereomeric or enantiomeric by-products are integrated and reported under ICH Q3A thresholds when the material is intended for active pharmaceutical ingredient route development. Equipment for this transformation includes a jacketed ultra-low-temperature stirred vessel with an internal temperature control band of ±3 °C; deviation above −50 °C increases competing C-4 enolate formation and subsequent dialkylated pyroglutamate by-products. Published kinetic data for this specific N-Boc methyl ester enolate at intermediate temperatures are limited, so kilo-scale campaigns should establish quench-time profiles using periodic reverse-phase HPLC and in situ ReactIR carbonyl disappearance data before committing to a fixed production cycle.

When DIBAL-H Is Restricted to Ester Reduction in the Presence of the Lactam Carbonyl

A 1.0–1.1 molar equivalent charge of diisobutylaluminium hydride in toluene reduces the methyl ester to the corresponding aldehyde at −78 °C, giving (S)-1-Boc-5-oxopyrrolidine-2-carbaldehyde. The lactam carbonyl remains largely unreduced under these conditions because the ester is more electrophilic and the low temperature suppresses over-reduction; aldehyde selectivity is lost when the DIBAL-H charge exceeds 1.3 equivalents or the reaction temperature rises above −60 °C, at which point lactam carbonyl reduction and dimerisation by-products increase. The crude aldehyde is used without chromatography in Horner-Wadsworth-Emmons or Wittig extensions after aqueous Rochelle salt work-up. In contrast, treatment with lithium borohydride in tetrahydrofuran at 0–25 °C and a charge of 1.5–2.0 mol equivalents yields (S)-1-Boc-5-oxopyrrolidine-2-methanol, a chiral alcohol building block retaining the γ-lactam ring. This alcohol is converted to the corresponding tert-butyldimethylsilyl ether, tosylate, or mesylate for subsequent substitution or oxidation. Terminal products include chiral pyrrolidinone fragments used in alkaloid core assembly and in ligand synthesis; the aldehyde route is preferred when a two-carbon chain extension is required, while the alcohol route is selected for nucleophilic displacement pathways. Residual toluene in isolated aldehyde streams is controlled to the ICH Q3C Class 2 limit of 890 ppm when the material enters pharmaceutical intermediate supply chains; tetrahydrofuran in the alcohol route is monitored under USP <467>. For development batches, a cryogenic stirred tank with temperature logging and slow DIBAL-H addition over 1–2 h is normal, while work-up vessels with bottom discharge valves reduce aluminium emulsion losses at the organic-aqueous interface.

Treatment with trifluoroacetic acid in dichloromethane at 1:1 v/v and 0–25 °C removes the Boc group from the lactam nitrogen while the methyl ester survives; after 1.5–3.0 h, the solvent is evaporated and the residue neutralised with saturated sodium bicarbonate to pH 7–8. Extraction with dichloromethane gives L-pyroglutamic acid methyl ester as the free form, which is acylated with substituted acid chlorides in tetrahydrofuran at 0 °C using triethylamine at 1.2–1.5 mol equivalents relative to substrate. The reaction is monitored by thin-layer chromatography with ethyl acetate/hexane 1:1 v/v and by LCMS until the secondary lactam NH is consumed; the resulting N-acyl pyroglutamate methyl esters are used as building blocks in parallel medicinal chemistry libraries where lactam-containing scaffolds are screened for metabolic stability and target affinity. Because the free lactam NH is a weak nucleophile, acylation times are typically 2–6 h, and excess acyl chloride above 1.5 equivalents tends to form the corresponding carboxylic acid after aqueous quench, complicating purification. Compliance for early discovery material is less stringent than for active pharmaceutical ingredient supply, but residual trifluoroacetic acid is quantified by ion chromatography and controlled by an internal specification aligned with ICH Q3A; dichloromethane and tetrahydrofuran content is monitored under USP <467> when the derivatives are shipped to a good manufacturing practice facility. Reactors for this sequence are simple glass or glass-lined vessels with an operating range of −10 °C to 40 °C, nitrogen blanketing, and acid-resistant wetted parts; the acid-neutralisation step is the most frequent source of loss because the methyl ester is vulnerable to saponification if the pH rises above 8.5 during sodium bicarbonate treatment.

Chiral Pool Entry into Pyrrolidine Alkaloid Scaffolds

In routes to fused pyrrolidine and indolizidine systems, (S)-1-tert-butyl 2-methyl 5-oxopyrrolidine-1,2-dicarboxylate is converted into the C-2 aldehyde or alcohol described above, then elaborated into olefinated or aminated intermediates that undergo cyclisation. Published syntheses of (−)-kainic acid and related kainoid glutamate analogues have used pyroglutamate-derived intermediates, with the N-Boc methyl ester providing a protected C-2 side chain and a masked lactam nitrogen for subsequent deprotection. The methyl ester is often retained through early carbon-carbon bond-forming steps because it stabilises the C-2 carbonyl pathway and suppresses unwanted β-elimination during organometallic additions. When a Grignard or alkyllithium addition to a C-2 aldehyde intermediate is selected for side-chain installation, the reagent is charged at 1.5–2.0 mol equivalents relative to substrate and the internal temperature is kept below −40 °C to suppress lactam carbonyl addition and enolate formation. Terminal products from this downstream track are not limited to single target compounds; the main utility lies in exposing the C-2, C-3, and C-4 positions of the pyrrolidinone ring to controlled substitution, yielding chiral fragments for central nervous system probe synthesis and alkaloid analogue programmes. Production is typically performed at laboratory to pilot scale in borosilicate glass reactors or 20–50 L glass-lined vessels with temperature control from −80 °C to 120 °C. Process safety assessments for these multi-step routes focus on diazo/azide reagents, hydride charges, and exothermic quench steps; batch records typically require differential scanning calorimetry screening for isolated intermediates and waste-stream pH control before discharge. Standard analytical characterisation follows ICH Q3A thresholds for isolated intermediates when the route is transferred to a contract manufacturing organisation; the absence of pharmacopoeial monographs for these advanced chiral intermediates means that in-house HPLC, chiral HPLC, and mass balance specifications are used instead.